Cullen/Frost Bankers, Inc. Acadia Pharmaceuticals Inc Transaction History
Cullen/Frost Bankers, Inc.
- $7.83 Billion
- Q2 2025
A detailed history of Cullen/Frost Bankers, Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 70 shares of ACAD stock, worth $1,491. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70
Previous 70
-0.0%
Holding current value
$1,491
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ACAD
# of Institutions
346Shares Held
163MCall Options Held
811KPut Options Held
334K-
Baker Bros. Advisors LP New York, NY42.9MShares$914 Million9.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.3MShares$325 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$257 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY9MShares$192 Million2.98% of portfolio
-
State Street Corp Boston, MA6.18MShares$132 Million0.01% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.45B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...